First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Restricted access

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.

Correspondence: Eddy S. Yang, MD, PhD, Department of Radiation Oncology, University of Alabama at Birmingham, 1700 6th Avenue S, HSROC Suite 2232N, Birmingham, AL 35249. Email: shyang@uabmc.edu

Supplementary Materials

    • Supplemental Material (PDF 85.4 KB)
All Time Past Year Past 30 Days
Abstract Views 2 0 0
Full Text Views 265 171 12
PDF Downloads 127 102 10
EPUB Downloads 0 0 0